SlideShare a Scribd company logo
Presentation on
POLYMORPHISM
Submitted to:
Dr.Mohammad Hossain Shariare
Associate Professor
Department of Pharmaceutical Sciences
North South University
Submitted By:
Name ID
Md. Muhib Islam Sarkar 1821381649
Israt Jahan 1821408649
Afsana Akter 1821414049
Sadia Haque Shoily 1821099649
S.M.M. Sharif Nowaz Antu 1821420049
A Presentation on Polymorphism
A Presentation on Polymorphism
A Presentation on Polymorphism
A Presentation on Polymorphism
ENANTIOTROPY
 1.Reversible phase
transition
 2.Metastable to stable
 3.Lower melting point
has lower heat of fusion
MONOTROPY
1. Irreversible phase
transition
2. metastable to stable
3.Higher melting point has
higher heat of fusion
4.Lower melting form is
thermodynamically stable below
the transition tempareture and high
m.p From is stable above the
transition tempareture
4.Higher melting form is always
thermodynamically stable form
Properties of polymorphs
Packing
properties
Thermodynamic
properties Kinetic
properties
Spectroscopic
properties
Surface
properties
Mechanical
properties
Stability characteristics of polymorph
 Depending upon relative stability there
are two forms of polymorph-
1)Stable form Less aqueous
solibility
2)Meta stable form High aqueous
solubility
STRUCTURAL APPREANCE OF
POLYMORPHISM
 Polymorphs can exist in different crystalline shape.
STRUCTURAL APPREANCE OF
POLYMORPHISM
 Different crystal forms of polymorphs of a
particular substance exhibit significance
differences in physical properties and chemical
reactivities.
 Exhibit difference in stabilities.
STRUCTURAL APPREANCE OF
POLYMORPHISM
 Paracetamol is known to have three
polymorphs.
Stable Form
1
Monoclinic
Meta stable form
2
Unstable form 3
Orthorhombic
Method to identify
polymorphism
:Optical crystallography
• Use in the identification of polymorphs crystal esist in
isotropic and anisotropic form
• Isotropic examine the velocity of light is same in all
direction.
• Anisotropic crystal have 2 or 3 different light
velocities or refractive index.
• Video recording system and polarizing microscope
filted during according to heating and cooling stage for
investigating polymorph.
X ray diffraction method
• It provide the most complete information about solid state.
• By this method one can identify the unit cell dimension &provide
specific differences between crystalline forms of given compound.
• In an X-ray diffraction measurement a crystal is mounted on a
goniometer and gradually rotated while being bombarded with X-ray
producing a diffraction pattern of regularly spaced sports known as
reflections.
• It is tedious time consuming so it is not used or unsuitable for
routine use.
• This method is based on the scattering of X-ray by crystals
Hot stage microscopy: Using this technique fluid phase
transformation as a function of temperature is observed. Generally
silicon oil hot stage microscopy is used for detection of pseudo
polymorphs.
NMR technique: In this technique, powder sample must be
rotated at a special angle with respect to magnetic field.
FTIR technique : It has been used to quantify binary mixtures of
polymorphs. In identification of polymorphs , only solid
samples (as mineral oil mulls & KBr pellets) can be used .
• In solutions polymorphs of a compound have identical spectra .
• Advantages: - Rapid.
• Technique is qualitative & quantitative.
• Dilatometry: Measure change in volume caused by thermal or chemical
effect.Using dilatometry the melting behaviour of Theobroma Oil
was studied .Extremely accurate but tedious , time consuming and
not widely used .
• Microcalorimetry: Used to characterize thermodynamic properties of
different molecules.
•
Thermal methods: a}DSC[Differential scanning calorimetry]
b}DTA[Differential thermal analysis]c} TGA [thermal gravimetric
analysis]
This method measures heat loss or gain from physical or chemical
chages occurring in sample which is recorded as a function of
temperature as substance is heated at uniform scale.
Advantage:
• I Thermodynamic parameter can be evaluated.
• II Heat of Transition from one polymorph to the other
Ref:https://www.slideshare.net/MahendraMahi28/polymorphism-142600438
Application of polymorphism
in pharmaceutical industry
To avoid manufacturing problem
For improvement of therapeutic activity of drug
To prevent loss of raw material
For better bioavailability of drug
Manufacturing
Problem
The knowledge of solid state properties in an early stage of
development helps to avoid manufacturing problems, to
fine the tune the performance of drugs and provides space
for innovations.
E.g.-Famotidine which is an excellent
histamine
H2 receptor antagonist is also found to exist in two
different polymorphic forms-
1.Metastable polymorph B
2.Stable polymorph A
Suspension
In preparation of suspension use of a wrong polymorph of a drug, a phase
conversion from the metastable to stable polymorph may occur. This result
in crystal growth and caking of suspension.
E.g.- cortisone acetate was one of the most difficult polymorphic
problems to solve.
Creams
When creams are prepared with the active ingredient
suspended in the cream base, use of the wrong polymorph
can result in a phase inversion to a more stable phase. As a
consequence, crystal growth can occur in the vehicle
yielding gritty, cosmetically unacceptable creams or
products in which the active ingredient is unevenly
distributed.
Solution
Flynn has reported some problem in the formulation of a
parenteral solution of a drug. In this instance,
determination of the water solubility of the compound
indicated the drug to be adequately soluble for the
concentration required in the formulation. Stability studies
on the formulation quickly turned up the presence of
precipitate.
Suppositories
The polymorphic changes of a suppository base could result
in a product that undergoes a change in its melting
characteristics. If the suppository base is of the type that
depends on melting at body temperatures to release the
active components of the formulations a relatively small
change in its melting point could have severe
consequences.
Polymorphism and Generically
Equivalent Dosage Forms
If the rate of absorption of the active ingredient in an oral
preparation is dissolution-rate dependent, the use of a
compound exhibiting polymorphism may lead to good or
bad consequences. The successful utilization of a
polymorph of significantly greater thermodynamic activity
(solubility) than the stable modification may provide, in
some instances, therapeutic blood levels from otherwise
inactive drugs.
Polymorphism of several drug
Drug Substance Polymorphism Aspect Bioavailability Issues in human
body
Ritonavir 1.Antiretroviral drug belonging to
protease inhibitor class and used
to treat HIV-1 infection
2.Exhibits conformational
polymorphism
Having total 5 forms
2 years after the launch of first
ritonavir product, several batches
failed dissoulation specifications
because the presence of a
different polymorphic form having
50% lower intrinsic solubility of
reference form
Oxytetracycline 1.It is a broad spectrum antibiotic
2.Exist in 2 different forms
1. Oxytetracycline showed
differences in patients' blood
levels
2. Differences in in vitro
dissolution of tablets
Continue….
Drug Substance Polymorphism Aspect Bioavailability Issues in human
body
Axitinib 1.It is a tyrosine kinase inhibitor
of endothelial growth factor of
tumor thus prevents growth of
cancer
2.60 solvates and 5 anhydrous
forms were discovered
1.The commercial formulation
under trade name INLYTA which
contains the stable anhydrous
form
Atrovastatin Calcium 1.Inhibitor of 3-hydroxyl-3-
methylglutaryl-coenzyme A
reductase
2.Strong ability to lowering blood
cholesterol
1.Ustable
2.The hydroxyl acid form is
converted to lactone form that is
15 times less soluble than the
hydroxyl form
3.After oral administration, the
absolute bioavailability of
atorvastatin is only 14%
Chloramphenicol Palmitate 1.It is a prodrug of
chloramphenicol with antibiotic
properties
2.Exibits 3 forms: Stable,
Metastable, Unstable
1.Metastable form dissolves faster
than stable form
2.Low serum levels for the stable
polymorph were observed.
Ref.:www.semanticscholar.org
Structure of some drug substances:
Ritonavir Oxytetracyclin Axitinib
Atrovastatin Calcium
Chloramphenicol
Palmitate
Regulatory consideration
 A sponsor of an Abbreviated New Drug Application (ANDA) must have
information in the context of generic product and innovator product
equivalency.
 Three decision trees for solid oral dosage forms or liquid suspensions are
provided for evaluating when and how polymorphs of drug substances should be
monitored and controlled in ANDA submissions.
 Case studies from ANDAs are provided which demonstrate the irrelevance of
polymorphism to the determination of drug substance “sameness”.
 In case of approval a new drug,US FDA states appropriate analytical procedures.
(Ref.:sciencedirect.com)
Conclusion
 Polymorphism have such serious consequences for the bioavailability of drugs
with low aqueous solubility
 polymorphic forms of a drug differ in the physicochemical properties
 To check purity/integrity of the API
 maintain the potency
 huge scope for further research
 Difference in the solubility and melting point
 Metastable form may lead to preferential choice of a polymorph other than
stable form
References
 Polymorph Impact on the Bioavailability and Stability of Poorly Soluble
Drugs:Roberta Censi, Piera Di Martino
https://www.sciencedirect.com/science/article/abs/pii/S0169409X03002
242
Wikipedia
https://www.semanticscholar.org/paper/Polymorph-Impact-on-the-
Bioavailability-and-of-Censi-
Martino/45efb7ee5d2393679561197104856379c075fa29

More Related Content

PPT
Polymorphism
PPTX
Seminar on polymorphism
PDF
Importance of Polymorphs in Pharma Industry by dr. amsavel
PPTX
Polymorphism
PDF
Polymorphism in Pharmaceuticals
PPT
Polymorphism in Pharmacy
PPTX
Polymorphism
PPT
Preformulation testing of solid dosage forms
Polymorphism
Seminar on polymorphism
Importance of Polymorphs in Pharma Industry by dr. amsavel
Polymorphism
Polymorphism in Pharmaceuticals
Polymorphism in Pharmacy
Polymorphism
Preformulation testing of solid dosage forms

What's hot (20)

PPTX
Pharmaceutical Suspensions and Emulsions
PPTX
Tablet coating defects and their remedies
PPTX
Co-solvency
PPTX
PARTITION COEFFICIENT
PPTX
Tablet coating defects
PPT
Drying- Pharmaceutical Engineering
PPTX
Flow properties of powders
PPT
PPT
Solubilization
PPTX
DISPERSE SYSTEM
PPTX
Chlorobutanol
PDF
Flow Properties of Powder: Industrial Pharmacy 1st
PPTX
Wet granulation
PDF
Synthesis of triphenyl imidazole
PPTX
Sensitization and protective colloidal action
PPTX
Drug stability
PDF
manufacturing of Parenterals.pdf
PPTX
Theories of emulsions
Pharmaceutical Suspensions and Emulsions
Tablet coating defects and their remedies
Co-solvency
PARTITION COEFFICIENT
Tablet coating defects
Drying- Pharmaceutical Engineering
Flow properties of powders
Solubilization
DISPERSE SYSTEM
Chlorobutanol
Flow Properties of Powder: Industrial Pharmacy 1st
Wet granulation
Synthesis of triphenyl imidazole
Sensitization and protective colloidal action
Drug stability
manufacturing of Parenterals.pdf
Theories of emulsions
Ad

Similar to A Presentation on Polymorphism (20)

PPTX
PPTX
Lec 2 polymorphism
PDF
polymorphism-160421053529.pdf
PPT
Polymorphism presentation of Pharmacy.ppt
PPTX
Solid State Pharmaceutics [Autosaved].pptx
PPT
Preformulation -1.- Industrial Pharmacyppt
PDF
How to handle drug polymorphs... case study of trelagliptin succinate
PDF
Evaluation of Various Polymorphs by Different Techniques and Their Characteri...
PPT
physicochemical_properties_of_drug_molecules.ppt
PPTX
polymorph.pptx
PPTX
Polymorph Screening in Drug Delelopment.pptx
PPTX
Polymorphism PP I-WPS Office (3).pptx
PPTX
BIO PHARMA PPT FOR FACTORS INFLUENCING DRUG ABSORPTION
PPTX
preformulation studies
PDF
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
PPT
0 preformulation (1)
PDF
1-2-PhysicalState of Matter.pdf
PPTX
State of matter (Physical Pharmacy)
PPTX
4_2018_03_07!07_18_04_AM.pptx
PPTX
Pharma
Lec 2 polymorphism
polymorphism-160421053529.pdf
Polymorphism presentation of Pharmacy.ppt
Solid State Pharmaceutics [Autosaved].pptx
Preformulation -1.- Industrial Pharmacyppt
How to handle drug polymorphs... case study of trelagliptin succinate
Evaluation of Various Polymorphs by Different Techniques and Their Characteri...
physicochemical_properties_of_drug_molecules.ppt
polymorph.pptx
Polymorph Screening in Drug Delelopment.pptx
Polymorphism PP I-WPS Office (3).pptx
BIO PHARMA PPT FOR FACTORS INFLUENCING DRUG ABSORPTION
preformulation studies
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
0 preformulation (1)
1-2-PhysicalState of Matter.pdf
State of matter (Physical Pharmacy)
4_2018_03_07!07_18_04_AM.pptx
Pharma
Ad

Recently uploaded (20)

PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
Slider: TOC sampling methods for cleaning validation
PPTX
Respiratory drugs, drugs acting on the respi system
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PDF
Khadir.pdf Acacia catechu drug Ayurvedic medicine
PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
LUNG ABSCESS - respiratory medicine - ppt
PPTX
Neuropathic pain.ppt treatment managment
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PDF
Neuro ED Bet Sexologist in Patna Bihar India Dr. Sunil Dubey
PPT
Management of Acute Kidney Injury at LAUTECH
PPT
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
PPTX
1 General Principles of Radiotherapy.pptx
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Slider: TOC sampling methods for cleaning validation
Respiratory drugs, drugs acting on the respi system
Medical Evidence in the Criminal Justice Delivery System in.pdf
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Khadir.pdf Acacia catechu drug Ayurvedic medicine
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
LUNG ABSCESS - respiratory medicine - ppt
Neuropathic pain.ppt treatment managment
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
Neuro ED Bet Sexologist in Patna Bihar India Dr. Sunil Dubey
Management of Acute Kidney Injury at LAUTECH
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
1 General Principles of Radiotherapy.pptx

A Presentation on Polymorphism

  • 1. Presentation on POLYMORPHISM Submitted to: Dr.Mohammad Hossain Shariare Associate Professor Department of Pharmaceutical Sciences North South University Submitted By: Name ID Md. Muhib Islam Sarkar 1821381649 Israt Jahan 1821408649 Afsana Akter 1821414049 Sadia Haque Shoily 1821099649 S.M.M. Sharif Nowaz Antu 1821420049
  • 6. ENANTIOTROPY  1.Reversible phase transition  2.Metastable to stable  3.Lower melting point has lower heat of fusion MONOTROPY 1. Irreversible phase transition 2. metastable to stable 3.Higher melting point has higher heat of fusion
  • 7. 4.Lower melting form is thermodynamically stable below the transition tempareture and high m.p From is stable above the transition tempareture 4.Higher melting form is always thermodynamically stable form
  • 8. Properties of polymorphs Packing properties Thermodynamic properties Kinetic properties Spectroscopic properties Surface properties Mechanical properties
  • 9. Stability characteristics of polymorph  Depending upon relative stability there are two forms of polymorph- 1)Stable form Less aqueous solibility 2)Meta stable form High aqueous solubility
  • 10. STRUCTURAL APPREANCE OF POLYMORPHISM  Polymorphs can exist in different crystalline shape.
  • 11. STRUCTURAL APPREANCE OF POLYMORPHISM  Different crystal forms of polymorphs of a particular substance exhibit significance differences in physical properties and chemical reactivities.  Exhibit difference in stabilities.
  • 12. STRUCTURAL APPREANCE OF POLYMORPHISM  Paracetamol is known to have three polymorphs. Stable Form 1 Monoclinic Meta stable form 2 Unstable form 3 Orthorhombic
  • 13. Method to identify polymorphism :Optical crystallography • Use in the identification of polymorphs crystal esist in isotropic and anisotropic form • Isotropic examine the velocity of light is same in all direction. • Anisotropic crystal have 2 or 3 different light velocities or refractive index. • Video recording system and polarizing microscope filted during according to heating and cooling stage for investigating polymorph.
  • 14. X ray diffraction method • It provide the most complete information about solid state. • By this method one can identify the unit cell dimension &provide specific differences between crystalline forms of given compound. • In an X-ray diffraction measurement a crystal is mounted on a goniometer and gradually rotated while being bombarded with X-ray producing a diffraction pattern of regularly spaced sports known as reflections. • It is tedious time consuming so it is not used or unsuitable for routine use. • This method is based on the scattering of X-ray by crystals
  • 15. Hot stage microscopy: Using this technique fluid phase transformation as a function of temperature is observed. Generally silicon oil hot stage microscopy is used for detection of pseudo polymorphs. NMR technique: In this technique, powder sample must be rotated at a special angle with respect to magnetic field.
  • 16. FTIR technique : It has been used to quantify binary mixtures of polymorphs. In identification of polymorphs , only solid samples (as mineral oil mulls & KBr pellets) can be used . • In solutions polymorphs of a compound have identical spectra . • Advantages: - Rapid. • Technique is qualitative & quantitative. • Dilatometry: Measure change in volume caused by thermal or chemical effect.Using dilatometry the melting behaviour of Theobroma Oil was studied .Extremely accurate but tedious , time consuming and not widely used .
  • 17. • Microcalorimetry: Used to characterize thermodynamic properties of different molecules. • Thermal methods: a}DSC[Differential scanning calorimetry] b}DTA[Differential thermal analysis]c} TGA [thermal gravimetric analysis] This method measures heat loss or gain from physical or chemical chages occurring in sample which is recorded as a function of temperature as substance is heated at uniform scale. Advantage: • I Thermodynamic parameter can be evaluated. • II Heat of Transition from one polymorph to the other Ref:https://www.slideshare.net/MahendraMahi28/polymorphism-142600438
  • 18. Application of polymorphism in pharmaceutical industry To avoid manufacturing problem For improvement of therapeutic activity of drug To prevent loss of raw material For better bioavailability of drug
  • 19. Manufacturing Problem The knowledge of solid state properties in an early stage of development helps to avoid manufacturing problems, to fine the tune the performance of drugs and provides space for innovations. E.g.-Famotidine which is an excellent histamine H2 receptor antagonist is also found to exist in two different polymorphic forms- 1.Metastable polymorph B 2.Stable polymorph A
  • 20. Suspension In preparation of suspension use of a wrong polymorph of a drug, a phase conversion from the metastable to stable polymorph may occur. This result in crystal growth and caking of suspension. E.g.- cortisone acetate was one of the most difficult polymorphic problems to solve.
  • 21. Creams When creams are prepared with the active ingredient suspended in the cream base, use of the wrong polymorph can result in a phase inversion to a more stable phase. As a consequence, crystal growth can occur in the vehicle yielding gritty, cosmetically unacceptable creams or products in which the active ingredient is unevenly distributed.
  • 22. Solution Flynn has reported some problem in the formulation of a parenteral solution of a drug. In this instance, determination of the water solubility of the compound indicated the drug to be adequately soluble for the concentration required in the formulation. Stability studies on the formulation quickly turned up the presence of precipitate.
  • 23. Suppositories The polymorphic changes of a suppository base could result in a product that undergoes a change in its melting characteristics. If the suppository base is of the type that depends on melting at body temperatures to release the active components of the formulations a relatively small change in its melting point could have severe consequences.
  • 24. Polymorphism and Generically Equivalent Dosage Forms If the rate of absorption of the active ingredient in an oral preparation is dissolution-rate dependent, the use of a compound exhibiting polymorphism may lead to good or bad consequences. The successful utilization of a polymorph of significantly greater thermodynamic activity (solubility) than the stable modification may provide, in some instances, therapeutic blood levels from otherwise inactive drugs.
  • 25. Polymorphism of several drug Drug Substance Polymorphism Aspect Bioavailability Issues in human body Ritonavir 1.Antiretroviral drug belonging to protease inhibitor class and used to treat HIV-1 infection 2.Exhibits conformational polymorphism Having total 5 forms 2 years after the launch of first ritonavir product, several batches failed dissoulation specifications because the presence of a different polymorphic form having 50% lower intrinsic solubility of reference form Oxytetracycline 1.It is a broad spectrum antibiotic 2.Exist in 2 different forms 1. Oxytetracycline showed differences in patients' blood levels 2. Differences in in vitro dissolution of tablets
  • 26. Continue…. Drug Substance Polymorphism Aspect Bioavailability Issues in human body Axitinib 1.It is a tyrosine kinase inhibitor of endothelial growth factor of tumor thus prevents growth of cancer 2.60 solvates and 5 anhydrous forms were discovered 1.The commercial formulation under trade name INLYTA which contains the stable anhydrous form Atrovastatin Calcium 1.Inhibitor of 3-hydroxyl-3- methylglutaryl-coenzyme A reductase 2.Strong ability to lowering blood cholesterol 1.Ustable 2.The hydroxyl acid form is converted to lactone form that is 15 times less soluble than the hydroxyl form 3.After oral administration, the absolute bioavailability of atorvastatin is only 14% Chloramphenicol Palmitate 1.It is a prodrug of chloramphenicol with antibiotic properties 2.Exibits 3 forms: Stable, Metastable, Unstable 1.Metastable form dissolves faster than stable form 2.Low serum levels for the stable polymorph were observed. Ref.:www.semanticscholar.org
  • 27. Structure of some drug substances: Ritonavir Oxytetracyclin Axitinib Atrovastatin Calcium Chloramphenicol Palmitate
  • 28. Regulatory consideration  A sponsor of an Abbreviated New Drug Application (ANDA) must have information in the context of generic product and innovator product equivalency.  Three decision trees for solid oral dosage forms or liquid suspensions are provided for evaluating when and how polymorphs of drug substances should be monitored and controlled in ANDA submissions.  Case studies from ANDAs are provided which demonstrate the irrelevance of polymorphism to the determination of drug substance “sameness”.  In case of approval a new drug,US FDA states appropriate analytical procedures. (Ref.:sciencedirect.com)
  • 29. Conclusion  Polymorphism have such serious consequences for the bioavailability of drugs with low aqueous solubility  polymorphic forms of a drug differ in the physicochemical properties  To check purity/integrity of the API  maintain the potency  huge scope for further research  Difference in the solubility and melting point  Metastable form may lead to preferential choice of a polymorph other than stable form
  • 30. References  Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs:Roberta Censi, Piera Di Martino https://www.sciencedirect.com/science/article/abs/pii/S0169409X03002 242 Wikipedia https://www.semanticscholar.org/paper/Polymorph-Impact-on-the- Bioavailability-and-of-Censi- Martino/45efb7ee5d2393679561197104856379c075fa29